In 120 patients with NSCLC who underwent surgery, Mitsudomi et al20 found that a p53 mutation was a significant prognostic factor for worse survival in the patients with advanced disease (stages IIIA‐IV) but not early disease (stages I‐II). Here, TP53 is linked to non-small cell lung carcinoma.